JP2007520450A - 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法 - Google Patents

非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法 Download PDF

Info

Publication number
JP2007520450A
JP2007520450A JP2006533951A JP2006533951A JP2007520450A JP 2007520450 A JP2007520450 A JP 2007520450A JP 2006533951 A JP2006533951 A JP 2006533951A JP 2006533951 A JP2006533951 A JP 2006533951A JP 2007520450 A JP2007520450 A JP 2007520450A
Authority
JP
Japan
Prior art keywords
cell
maytansinoid
ester
antibody
monoclonal antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006533951A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007520450A5 (US20080114153A1-20080515-C00016.png
Inventor
スティーブス，リタ
ルッツ，ロバート
チャリ，ラヴィ
シェ，ホンシェン
コフトゥン，イェレナ
Original Assignee
イミュノジェン・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34467962&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2007520450(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by イミュノジェン・インコーポレーテッド filed Critical イミュノジェン・インコーポレーテッド
Publication of JP2007520450A publication Critical patent/JP2007520450A/ja
Publication of JP2007520450A5 publication Critical patent/JP2007520450A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
JP2006533951A 2003-10-10 2004-10-12 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法 Pending JP2007520450A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50990103P 2003-10-10 2003-10-10
US10/960,602 US8088387B2 (en) 2003-10-10 2004-10-08 Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
PCT/US2004/030917 WO2005037992A2 (en) 2003-10-10 2004-10-12 Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011148625A Division JP5718745B2 (ja) 2003-10-10 2011-07-04 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法

Publications (2)

Publication Number Publication Date
JP2007520450A true JP2007520450A (ja) 2007-07-26
JP2007520450A5 JP2007520450A5 (US20080114153A1-20080515-C00016.png) 2011-01-27

Family

ID=34467962

Family Applications (10)

Application Number Title Priority Date Filing Date
JP2006533951A Pending JP2007520450A (ja) 2003-10-10 2004-10-12 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法
JP2011148625A Active JP5718745B2 (ja) 2003-10-10 2011-07-04 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法
JP2014078553A Active JP5926759B2 (ja) 2003-10-10 2014-04-07 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法
JP2016021695A Pending JP2016135786A (ja) 2003-10-10 2016-02-08 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法
JP2017114877A Withdrawn JP2017200934A (ja) 2003-10-10 2017-06-12 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法
JP2018187555A Pending JP2019011363A (ja) 2003-10-10 2018-10-02 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法
JP2019038151A Pending JP2019142864A (ja) 2003-10-10 2019-03-04 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法
JP2020132965A Withdrawn JP2020189854A (ja) 2003-10-10 2020-08-05 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法
JP2022023780A Withdrawn JP2022068295A (ja) 2003-10-10 2022-02-18 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法
JP2024025206A Pending JP2024059792A (ja) 2003-10-10 2024-02-22 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法

Family Applications After (9)

Application Number Title Priority Date Filing Date
JP2011148625A Active JP5718745B2 (ja) 2003-10-10 2011-07-04 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法
JP2014078553A Active JP5926759B2 (ja) 2003-10-10 2014-04-07 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法
JP2016021695A Pending JP2016135786A (ja) 2003-10-10 2016-02-08 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法
JP2017114877A Withdrawn JP2017200934A (ja) 2003-10-10 2017-06-12 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法
JP2018187555A Pending JP2019011363A (ja) 2003-10-10 2018-10-02 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法
JP2019038151A Pending JP2019142864A (ja) 2003-10-10 2019-03-04 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法
JP2020132965A Withdrawn JP2020189854A (ja) 2003-10-10 2020-08-05 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法
JP2022023780A Withdrawn JP2022068295A (ja) 2003-10-10 2022-02-18 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法
JP2024025206A Pending JP2024059792A (ja) 2003-10-10 2024-02-22 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法

Country Status (25)

Country Link
US (10) US8088387B2 (US20080114153A1-20080515-C00016.png)
EP (4) EP2612682A3 (US20080114153A1-20080515-C00016.png)
JP (10) JP2007520450A (US20080114153A1-20080515-C00016.png)
KR (4) KR101573124B1 (US20080114153A1-20080515-C00016.png)
CN (3) CN107198778A (US20080114153A1-20080515-C00016.png)
AU (2) AU2004282491C1 (US20080114153A1-20080515-C00016.png)
BE (1) BE2013C075I2 (US20080114153A1-20080515-C00016.png)
BR (1) BRPI0415448A8 (US20080114153A1-20080515-C00016.png)
CA (2) CA2542128C (US20080114153A1-20080515-C00016.png)
CY (2) CY1113984T1 (US20080114153A1-20080515-C00016.png)
DK (1) DK1689846T3 (US20080114153A1-20080515-C00016.png)
EA (1) EA010508B1 (US20080114153A1-20080515-C00016.png)
EC (1) ECSP066461A (US20080114153A1-20080515-C00016.png)
ES (1) ES2404304T3 (US20080114153A1-20080515-C00016.png)
HK (1) HK1244452A1 (US20080114153A1-20080515-C00016.png)
HR (1) HRP20130412T1 (US20080114153A1-20080515-C00016.png)
HU (1) HUS1300075I1 (US20080114153A1-20080515-C00016.png)
IL (4) IL173625A (US20080114153A1-20080515-C00016.png)
LU (1) LU92336I2 (US20080114153A1-20080515-C00016.png)
NO (2) NO337458B1 (US20080114153A1-20080515-C00016.png)
NZ (2) NZ545195A (US20080114153A1-20080515-C00016.png)
PL (1) PL1689846T3 (US20080114153A1-20080515-C00016.png)
PT (1) PT1689846E (US20080114153A1-20080515-C00016.png)
SI (1) SI1689846T1 (US20080114153A1-20080515-C00016.png)
WO (1) WO2005037992A2 (US20080114153A1-20080515-C00016.png)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013504585A (ja) * 2009-09-09 2013-02-07 セントローズ， エルエルシー 細胞外標的化薬物複合体
JP2013506709A (ja) * 2009-10-06 2013-02-28 イミュノジェン・インコーポレーテッド 有効なコンジュゲートおよび親水性リンカー
JP2013544253A (ja) * 2010-11-17 2013-12-12 ジェネンテック， インコーポレイテッド アラニニルメイタンシノール抗体コンジュゲート
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
JP2016106222A (ja) * 2009-10-26 2016-06-16 ネステク ソシエテ アノニム 抗ｔｎｆ薬及び自己抗体の検出用アッセイ
JP2016518332A (ja) * 2013-03-13 2016-06-23 ノバルティス アーゲー 抗体薬物コンジュゲート
WO2019150985A1 (ja) * 2018-01-31 2019-08-08 国立大学法人東京大学 抗体薬物複合体及びそれを含む医薬組成物

Families Citing this family (285)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2266607A3 (en) 1999-10-01 2011-04-20 Immunogen, Inc. Immunoconjugates for treating cancer
US7097840B2 (en) * 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
WO2002092771A2 (en) 2001-05-11 2002-11-21 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
US20090068178A1 (en) * 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
US20050276812A1 (en) * 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
NZ571508A (en) * 2002-05-24 2010-05-28 Schering Corp Neutralizing human anti-IGFR antibody
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) * 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
EP1718667B1 (en) * 2004-02-23 2013-01-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US20060045877A1 (en) * 2004-08-30 2006-03-02 Goldmakher Viktor S Immunoconjugates targeting syndecan-1 expressing cells and use thereof
NZ580115A (en) 2004-09-23 2010-10-29 Genentech Inc Cysteine engineered antibody light chains and conjugates
JP4993645B2 (ja) 2004-12-01 2012-08-08 ジェネンテック， インコーポレイテッド 抗体薬剤結合体および方法
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
AU2006213662B2 (en) * 2005-02-11 2010-08-05 Immunogen, Inc. Process for preparing stable drug conjugates
MX2007012896A (es) * 2005-04-15 2007-12-10 Schering Corp Metodos y composiciones para tratamiento o prevencion de cancer.
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
ES2533992T3 (es) * 2005-08-24 2015-04-16 Immunogen, Inc. Procedimiento para preparar conjugados de anticuerpo maitansinoide
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
WO2007100385A2 (en) * 2005-10-31 2007-09-07 Genentech, Inc. Macrocyclic depsipeptide antibody-drug conjugates and methods
CN101410413B (zh) 2006-01-20 2013-04-24 健泰科生物技术公司 抗ephrinb2抗体及其使用方法
AR059851A1 (es) 2006-03-16 2008-04-30 Genentech Inc Anticuerpos de la egfl7 y metodos de uso
WO2007140371A2 (en) 2006-05-30 2007-12-06 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
EP2061814B1 (en) 2006-10-27 2012-06-06 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
MX2009007987A (es) 2007-01-25 2010-03-01 Dana Farber Cancer Inst Inc Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante.
US9023356B2 (en) 2007-03-15 2015-05-05 Ludwig Institute For Cancer Research Ltd Treatment method using EGFR antibodies and SRC inhibitors and related formulations
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
MX2009009912A (es) 2007-03-27 2010-01-18 Sea Lane Biotechnologies Llc Constructos y colecciones que comprenden secuencias de cadena ligera sustitutas de anticuerpos.
US20090011060A1 (en) * 2007-07-06 2009-01-08 Peter Koepke Campsiandra angustifolia extract and methods of extracting and using such extract
CA2692819A1 (en) 2007-07-16 2009-01-22 Genentech, Inc. Humanized anti-cd79b antibodies and immunoconjugates and methods of use
PE20140614A1 (es) 2007-07-16 2014-05-28 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados
JP5532486B2 (ja) 2007-08-14 2014-06-25 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Ｅｇｆ受容体を標的とするモノクローナル抗体１７５ならびにその誘導体および用途
EP3388086B1 (en) 2007-08-17 2020-10-07 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US7879369B2 (en) 2007-09-18 2011-02-01 Selvamedica, Llc Combretum laurifolium Mart. extract and methods of extracting and using such extract
SI2247620T1 (sl) 2008-01-31 2016-09-30 Genentech, Inc. Protitelesa proti CD79b in imunokonjugati in postopki za uporabo
EP3692988A3 (en) 2008-03-18 2020-10-14 Genentech, Inc. Combinations of an anti-her2 antibody-drug conjugate and 5-fu, anti-vegf antibody, carboplatin or abt-869 and methods of use
WO2009134870A1 (en) * 2008-04-30 2009-11-05 Immunogen, Inc. Potent cell-binding agent drug conjugates
US20100092495A1 (en) * 2008-04-30 2010-04-15 Immunogen Inc. Potent cell-binding agent drug conjugates
EP2276506A4 (en) 2008-04-30 2014-05-07 Immunogen Inc EFFICIENT CONJUGATES AND HYDROPHILIC BINDER
KR20230003298A (ko) 2008-04-30 2023-01-05 이뮤노젠 아이엔씨 가교제 및 그 용도
ES2442024T3 (es) 2008-07-15 2014-02-07 Academia Sinica Matrices de glucano sobre portaobjetos de vidrio revestidos con aluminio de tipo PTFE y métodos relacionados
IL271761B (en) 2009-02-05 2022-09-01 Immunogen Inc (12as)-8-methoxy-9-benzyloxy-11,12,12a,13-tetrahydro-6h-indolo[2,1-c][1,4]benzodiazepine-6-one, 4-benzyloxy-5-methoxy -2-nitrobenzoic acid and a process for their preparation
ES2932874T3 (es) * 2009-03-25 2023-01-27 Genentech Inc Anticuerpos anti-FGFR3 y métodos que utilizan los mismos
CN102471380B (zh) 2009-04-01 2015-01-14 霍夫曼-拉罗奇有限公司 抗FcRH5抗体和免疫偶联物及使用方法
JP5501439B2 (ja) 2009-04-02 2014-05-21 ロシュ グリクアート アクチェンゲゼルシャフト 完全長抗体と単鎖Ｆａｂフラグメントとを含む多重特異的抗体
JP5863640B2 (ja) 2009-04-29 2016-02-16 バイオ−ラッド ラボラトリーズ インコーポレーティッド 免疫複合体の精製
AU2010249046A1 (en) 2009-05-13 2011-12-01 Sea Lane Biotechnologies, Llc Neutralizing molecules to influenza viruses
KR102444399B1 (ko) 2009-06-03 2022-09-16 이뮤노젠 아이엔씨 메이탄시노이드의 제조방법
PL2437785T3 (pl) 2009-06-04 2015-08-31 Novartis Ag Sposoby identyfikacji miejsc sprzęgania IgG
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
CN104945509A (zh) 2009-09-16 2015-09-30 弗·哈夫曼-拉罗切有限公司 包含卷曲螺旋和/或系链的蛋白质复合体及其用途
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US20110165155A1 (en) * 2009-12-04 2011-07-07 Genentech, Inc. Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
CA2781682A1 (en) 2009-12-04 2011-06-09 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
MX2012007379A (es) 2009-12-23 2012-08-31 Genentech Inc Anticuerpos anti-bv8 y usos de los mismos.
AU2011215900A1 (en) 2010-02-10 2012-07-26 Immunogen, Inc. CD20 antibodies and uses thereof
EP2538981B1 (en) 2010-02-23 2017-12-20 F. Hoffmann-La Roche AG Compositions and methods for the diagnosis and treatment of tumor
SG10201501342UA (en) 2010-02-24 2015-04-29 Immunogen Inc Folate receptor 1 antibodies and immunoconjugates and uses thereof
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
MX338932B (es) 2010-03-12 2016-05-06 Immunogen Inc Moleculas de union cd37 y sus inmunoconjugados.
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
RU2624027C2 (ru) 2010-04-23 2017-06-30 Дженентек, Инк. Получение гетеромультимерных белков
KR20130098165A (ko) 2010-06-03 2013-09-04 제넨테크, 인크. 항체 및 면역접합체의 이뮤노-ｐｅｔ 영상화 및 그의 용도
CN114246952A (zh) 2010-06-08 2022-03-29 基因泰克公司 半胱氨酸改造的抗体和偶联物
WO2012019024A2 (en) 2010-08-04 2012-02-09 Immunogen, Inc. Her3-binding molecules and immunoconjugates thereof
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
EA201390472A1 (ru) 2010-10-29 2014-02-28 Иммьюноджен, Инк. Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты
AU2011320318B9 (en) * 2010-10-29 2015-11-19 Immunogen, Inc. Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
EP2655413B1 (en) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
EP2668209B8 (en) 2011-01-24 2021-08-11 Gilead Sciences, Inc. Antibodies selective for cells presenting egfr at high density
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
CA2825064C (en) 2011-02-04 2022-08-30 Genentech, Inc. Fc variants and methods for their production
RU2748733C2 (ru) 2011-02-15 2021-05-31 Иммуноджен, Инк. Цитотоксические производные бензодиазепина
MX2013011201A (es) * 2011-03-29 2013-12-16 Immunogen Inc Proceso para la elaboracion de conjugados de mejor homogeneidad.
UA116524C2 (uk) 2011-03-29 2018-04-10 Іммуноджен, Інк. Спосіб одержання кон'югата антитіло-майтансиноїд
MY171008A (en) 2011-03-29 2019-09-23 Immunogen Inc Preparation of maytansinoid antibody conjugates by a one-step process
MX2013011385A (es) 2011-04-01 2014-03-13 Immunogen Inc Moleculas de union a cd37 y sus inmunoconjugados.
SG193514A1 (en) 2011-04-01 2013-10-30 Immunogen Inc Methods for increasing efficacy of folr1 cancer therapy
US20140161827A1 (en) 2011-05-09 2014-06-12 University Of Virginia Patent Foundation Compositions and methods for treating cancer
CN103857699B (zh) 2011-05-24 2016-08-31 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
WO2012171020A1 (en) 2011-06-10 2012-12-13 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
US9289512B2 (en) 2011-06-21 2016-03-22 Immunogen, Inc. Maytansinoid derivatives with peptide linker and conjugates thereof
US10300140B2 (en) 2011-07-28 2019-05-28 I2 Pharmaceuticals, Inc. Sur-binding proteins against ERBB3
KR102007055B1 (ko) 2011-09-22 2019-08-02 암젠 인크 Cd27l 항원 결합 단백질
WO2013049521A2 (en) * 2011-09-29 2013-04-04 Virginia Commonwealth University Light-enabled drug delivery
WO2013063001A1 (en) 2011-10-28 2013-05-02 Genentech, Inc. Therapeutic combinations and methods of treating melanoma
CA2855746A1 (en) 2011-11-16 2013-05-23 John Stephen HILL Methods of treating epidermal growth factor deletion mutant viii related disorders
CA2856411A1 (en) 2011-11-21 2013-05-30 Immunogen, Inc. Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate
RU2632108C2 (ru) 2011-12-08 2017-10-02 Биотест Аг Применения иммуноконъюгатов, мишенью которых является cd138
ES2710916T3 (es) 2011-12-22 2019-04-29 I2 Pharmaceuticals Inc Proteínas de unión sustitutas
US9717803B2 (en) 2011-12-23 2017-08-01 Innate Pharma Enzymatic conjugation of polypeptides
AU2013209512B2 (en) 2012-01-20 2017-08-03 I2 Pharmaceuticals, Inc. Surrobody cojugates
BR112014019579A2 (pt) 2012-02-10 2019-10-15 Genentech, Inc Anticorpo de cadeia única, polinucleotídeo, vetor, célula hospedeira, método de produção de um anticorpo de cadeia única, heteromultímero e método de produção do heteromultímero
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
CA2869704A1 (en) * 2012-04-04 2013-10-10 Perseus Proteomics Inc. Drug conjugate comprising anti-cdh3 (pcadherin) antibody
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
JP2015516813A (ja) 2012-04-27 2015-06-18 シトムクス セラピューティクス，インコーポレイティド 上皮成長因子受容体を結合する活性化可能抗体及びその使用方法
MX2014012889A (es) 2012-05-01 2014-11-14 Genentech Inc Anticuerpos e inmunoconjugados anti-pmel17.
BR112014028222A2 (pt) 2012-05-15 2017-06-27 Seattle Genetics Inc conjugados vinculadores auto-estabilizantes.
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
EP3925627A1 (en) 2012-05-15 2021-12-22 Concortis Biosystems, Corp Drug-conjugates and uses thereof
CA2872327A1 (en) 2012-05-21 2013-11-28 Genentech, Inc. Anti-ly6e antibodies and immunoconjugates and methods of use
WO2014001325A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
RU2639287C2 (ru) 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
BR112015002193A2 (pt) 2012-08-02 2017-07-04 Genentech Inc anticorpos anti-etbr e imunoconjugados
KR20150032886A (ko) 2012-08-02 2015-03-30 제넨테크, 인크. 항-etbr 항체 및 면역접합체
US9914956B2 (en) 2012-08-18 2018-03-13 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
EP3486248B1 (en) 2012-09-26 2021-04-07 ImmunoGen, Inc. Improved methods for the acylation of maytansinol
RU2661083C2 (ru) 2012-10-04 2018-07-11 Иммуноджен, Инк. Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент - цитотоксический агент
WO2014078484A1 (en) 2012-11-15 2014-05-22 Endocyte, Inc. Conjugates for treating diseases caused by psma expressing cells
JP6133431B2 (ja) 2012-11-24 2017-05-24 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
CN104650113A (zh) * 2012-12-21 2015-05-27 百奥泰生物科技(广州)有限公司 类美登素衍生物及其制备方法和用途
CN103333246B (zh) * 2012-12-21 2015-09-16 百奥泰生物科技(广州)有限公司 一种抗egfr受体的肿瘤生长抑制剂及其制备方法和用途
JP6423804B2 (ja) 2013-02-28 2018-11-14 イミュノジェン・インコーポレーテッド 細胞結合剤及び細胞毒性剤を含む複合体
EP2961434A2 (en) 2013-02-28 2016-01-06 ImmunoGen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
US9415118B2 (en) * 2013-03-13 2016-08-16 Novartis Ag Antibody drug conjugates
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
KR20150127199A (ko) 2013-03-14 2015-11-16 제넨테크, 인크. 항-b7-h4 항체 및 면역접합체
WO2014140300A1 (en) 2013-03-15 2014-09-18 Innate Pharma Solid phase tgase-mediated conjugation of antibodies
MA38396B1 (fr) 2013-03-15 2019-05-31 Novartis Ag Anticorps medicamenteux conjugues et leurs compositions pharmaceutiques pour traiter un cancer positif a ckit
US10570151B2 (en) 2013-03-15 2020-02-25 Regeneron Pharmaceuticals, Inc. Biologically active molecules, conjugates thereof, and therapeutic uses
JP6574754B2 (ja) 2013-03-19 2019-09-11 ベイジン シェノゲン ファーマ グループ リミテッド エストロゲン受容体関連疾患を処置するための抗体及び方法
WO2014182970A1 (en) 2013-05-08 2014-11-13 Zymeworks Inc. Bispecific her2 and her3 antigen binding constructs
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
GB201309807D0 (en) 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
KR20160018579A (ko) * 2013-06-04 2016-02-17 싸이톰스 테라퓨틱스, 인크. 활성화가능 항체를 접합하기 위한 조성물 및 방법
BR112015032200A2 (pt) 2013-06-24 2017-11-21 Hanwha Chemical Corp conjugado anticorpo-droga com estabilidade melhorada, método de preparação, composição farmacêutica e uso do mesmo
EP3013365B1 (en) 2013-06-26 2019-06-05 Academia Sinica Rm2 antigens and use thereof
WO2014210564A1 (en) 2013-06-27 2014-12-31 Academia Sinica Glycan conjugates and use thereof
CN105473616B (zh) 2013-07-05 2020-08-04 形成生物产品有限公司 Egfr抗体缀合物
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
RU2560699C2 (ru) * 2013-08-02 2015-08-20 федеральное государственное автономное образовательное учреждение высшего профессионального образования "Национальный исследовательский ядерный университет МИФИ" (НИЯУ МИФИ) Способ создания наноразмерной диагностической метки на основе конъюгатов наночастиц и однодоменных антител
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
WO2015031396A1 (en) 2013-08-26 2015-03-05 Regeneron Pharmaceuticals, Inc. Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
KR102310441B1 (ko) 2013-09-05 2021-10-07 더 잭슨 래보라토리 Rna-염색질 상호작용 분석용 조성물 및 이의 용도
CA2923579C (en) 2013-09-06 2023-09-05 Academia Sinica Human inkt cell activation using glycolipids with altered glycosyl groups
EP3046940B1 (en) 2013-09-17 2019-07-03 F.Hoffmann-La Roche Ag Methods of using anti-lgr5 antibodies
US20150132323A1 (en) 2013-10-08 2015-05-14 Immunogen, Inc. Anti-FOLR1 Immunoconjugate Dosing Regimens
KR102087850B1 (ko) 2013-10-11 2020-03-12 메르사나 테라퓨틱스, 인코포레이티드 단백질-고분자-약물 접합체
KR102355745B1 (ko) 2013-10-11 2022-01-26 아사나 바이오사이언시스 엘엘씨 단백질-폴리머-약물 접합체
HUE051389T2 (hu) 2013-10-15 2021-03-01 Seagen Inc Pegilezett gyógyszer-linkerek ligandum-gyógyszer konjugátum javított farmakokinetikájához
CA2934030A1 (en) 2013-10-15 2015-04-23 Sorrento Therapeutics Inc. Drug-conjugates with a targeting molecule and two different drugs
MY194484A (en) 2013-10-18 2022-11-30 Deutsches Krebsforsch Labeled Inhibitors of Prostate Specific Membrane Antigen (PSMA), Their use as Imaging Agents and Pharmaceutical Agents for the Treatment of Prostate Cancer
US9290578B2 (en) 2013-10-21 2016-03-22 Genentech, Inc. Anti-Ly6E antibodies and methods of use
US9540440B2 (en) 2013-10-30 2017-01-10 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
AU2014348552A1 (en) 2013-11-13 2016-06-02 Zymeworks Inc. Monovalent antigen binding constructs targeting EGFR and/or HER2 and uses thereof
JP6817064B2 (ja) 2013-11-27 2021-01-20 ザイムワークス，インコーポレイテッド Ｈｅｒ２を標的とする二重特異性抗原結合性コンストラクト
WO2015089283A1 (en) 2013-12-11 2015-06-18 Cytomx Therapeutics, Inc. Antibodies that bind activatable antibodies and methods of use thereof
TWI541022B (zh) 2013-12-18 2016-07-11 應克隆公司 針對纖維母細胞生長因子受體－３（ｆｇｆｒ３）之化合物及治療方法
FI3082878T3 (fi) 2013-12-19 2022-12-15 Metyleenikarbamaatin linkkerit käytettäviksi kohdennettujen lääkeaineiden konjugaattien kanssa
US10214584B2 (en) 2014-01-15 2019-02-26 Order-Made Medical Research Inc. Therapeutic pharmaceutical composition employing anti-SLC6A6 antibody
US9943606B2 (en) 2014-01-15 2018-04-17 Rutgers, The State University Of New Jersey Dendritic polypeptide-based nanocarriers for the delivery of therapeutic agents
AU2015206370A1 (en) 2014-01-16 2016-07-07 Academia Sinica Compositions and methods for treatment and detection of cancers
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
AU2015208814B2 (en) 2014-01-27 2018-11-01 Pfizer Inc. Bifunctional cytotoxic agents
MX2016009332A (es) * 2014-01-29 2016-12-20 Shanghai hengrui pharmaceutical co ltd Conjugado de farmaco citotoxico-ligando, metodo de preparacion del mismo y uso del mismo.
MX2016010295A (es) 2014-02-11 2016-10-17 Seattle Genetics Inc Reduccion selectiva de proteinas.
US10464955B2 (en) 2014-02-28 2019-11-05 Hangzhou Dac Biotech Co., Ltd. Charged linkers and their uses for conjugation
CN106415244B (zh) 2014-03-27 2020-04-24 中央研究院 反应性标记化合物及其用途
BR122021009041B1 (pt) 2014-05-06 2022-11-29 Genentech, Inc Métodos para a preparação de uma proteína heteromultimérica
KR20220151036A (ko) 2014-05-27 2022-11-11 아카데미아 시니카 항-ｃｄ20 글리코항체 및 이의 용도
KR20230033737A (ko) 2014-05-27 2023-03-08 아카데미아 시니카 증진된 항체 효능을 위한 범용 당형태에 관한 조성물 및 방법
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
EP3149037A4 (en) 2014-05-27 2018-01-10 Academia Sinica Anti-her2 glycoantibodies and uses thereof
KR102494193B1 (ko) 2014-05-28 2023-01-31 아카데미아 시니카 항-ｔｎｆ-알파 글리코항체 및 이의 용도
ES2785551T3 (es) 2014-06-30 2020-10-07 Glykos Finland Oy Derivado de sacárido de una carga útil tóxica y sus conjugados con anticuerpos
WO2016004043A1 (en) * 2014-06-30 2016-01-07 Blend Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
EP3160518A4 (en) * 2014-06-30 2018-05-23 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
WO2016008112A1 (en) 2014-07-16 2016-01-21 Medshine Discovery Inc. Linkers and application towards adc thereof
WO2016024195A1 (en) 2014-08-12 2016-02-18 Novartis Ag Anti-cdh6 antibody drug conjugates
WO2016036861A1 (en) 2014-09-02 2016-03-10 Immunogen, Inc. Methods for formulating antibody drug conjugate compositions
WO2016036804A1 (en) 2014-09-03 2016-03-10 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
TWI697493B (zh) 2014-09-03 2020-07-01 美商免疫原公司 細胞毒性苯并二氮呯衍生物
WO2016040369A2 (en) 2014-09-08 2016-03-17 Academia Sinica HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
JP6473226B2 (ja) 2014-09-11 2019-02-20 シアトル ジェネティックス， インコーポレイテッド 第３級アミン含有薬物物質の標的送達
CN106804108B (zh) 2014-09-12 2021-08-10 基因泰克公司 抗-b7-h4抗体及免疫缀合物
KR20170052600A (ko) 2014-09-12 2017-05-12 제넨테크, 인크. 시스테인 가공된 항체 및 콘주게이트
EP3689910A3 (en) 2014-09-23 2020-12-02 F. Hoffmann-La Roche AG Method of using anti-cd79b immunoconjugates
US10835616B2 (en) 2014-10-14 2020-11-17 Polytherics Limited Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of PEG
EA201791050A1 (ru) 2014-11-14 2017-09-29 Новартис Аг Конъюгаты антител и лекарственных средств
ES2764111T3 (es) 2014-12-03 2020-06-02 Hoffmann La Roche Anticuerpos multiespecíficos
EA039794B1 (ru) 2014-12-04 2022-03-15 Селджин Корпорейшн Конъюгаты биомолекул
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
CA2972072A1 (en) 2015-01-24 2016-07-28 Academia Sinica Novel glycan conjugates and methods of use thereof
US10590165B2 (en) 2015-01-28 2020-03-17 Sorrento Therapeutics, Inc. Antibody drug conjugates
KR102046862B1 (ko) 2015-03-20 2019-11-20 화이자 인코포레이티드 Cti 약물작용발생단을 함유하는 이관능성 세포독성제
CA2980189A1 (en) 2015-04-24 2016-10-27 Genentech, Inc. Multispecific antigen-binding proteins
TW201711702A (zh) 2015-06-04 2017-04-01 應克隆公司 使用針對纖維母細胞生長因子受體３（ｆｇｆｒ３）之化合物的療法
US20170000900A1 (en) 2015-06-08 2017-01-05 Immunogen, Inc. Anti-cd37 immunoconjugate and anti-cd20 antibody combinations
CN106243127B (zh) * 2015-06-09 2021-01-26 凯惠科技发展(上海)有限公司 抗体药物偶联物、中间体、制备方法、药物组合物及应用
US20190194315A1 (en) 2015-06-17 2019-06-27 Novartis Ag Antibody drug conjugates
MD3313845T2 (ro) 2015-06-29 2021-02-28 Immunogen Inc Conjugați cu anticorpi având cisteină modificată prin inginerie genetică
WO2017003940A1 (en) * 2015-06-30 2017-01-05 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
AU2015242213A1 (en) 2015-07-12 2018-03-08 Hangzhou Dac Biotech Co., Ltd Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
US10081640B2 (en) 2015-07-21 2018-09-25 Immunogen, Inc. Methods of preparing cytotoxic benzodiazepine derivatives
EP3331569A1 (en) 2015-08-07 2018-06-13 Gamamabs Pharma Antibodies, antibody drug conjugates and methods of use
MA42706A (fr) 2015-08-28 2021-04-14 Debiopharm Int Sa Anticorps et dosages pour la détection de cd37
CN108348604B (zh) * 2015-09-08 2022-04-29 沃特世科技公司 用于分析抗体-药物缀合物的多维色谱方法
CN108601828B (zh) 2015-09-17 2023-04-28 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
KR20180069839A (ko) 2015-10-08 2018-06-25 자임워크스 인코포레이티드 카파 및 람다 경사슬을 포함하는 항원-결합 폴리펩티드 구조체 및 이의 용도
AU2016343817B2 (en) 2015-10-28 2021-05-27 Tva (Abc), Llc SSTR-targeted conjugates and particles and formulations thereof
RS65120B1 (sr) 2015-11-25 2024-02-29 Immunogen Inc Farmaceutske formulacije i postupci za njihovu upotrebu
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
US11229708B2 (en) 2015-12-04 2022-01-25 Seagen Inc. Conjugates of quaternized tubulysin compounds
BR112018014759B1 (pt) 2016-01-25 2024-02-27 Regeneron Pharmaceuticals, Inc Compostos derivados de maitasinoide e seus conjugados, composição compreendendo os mesmos, seus métodos de fabricação e uso
EP3411396A1 (en) 2016-02-04 2018-12-12 Curis, Inc. Mutant smoothened and methods of using the same
AU2016202632B2 (en) 2016-02-04 2021-09-09 Hangzhou Dac Biotech Co, Ltd Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
US10548881B2 (en) 2016-02-23 2020-02-04 Tarveda Therapeutics, Inc. HSP90 targeted conjugates and particles and formulations thereof
JP2019515876A (ja) 2016-03-08 2019-06-13 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｎ−グリカンおよびそのアレイのモジュール合成のための方法
SG11201807827VA (en) 2016-03-25 2018-10-30 Seattle Genetics Inc Process for the preparation of pegylated drug-linkers and intermediates thereof
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
WO2018009916A1 (en) 2016-07-07 2018-01-11 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
CN109562152B (zh) 2016-08-09 2024-04-02 西雅图基因公司 含有具有改善的生理化学性质的自稳定性接头的药物缀合物
US9950070B2 (en) * 2016-08-16 2018-04-24 Korea University Research And Business Foundation HER2 aptamer-anticancer drug complex for cancer cell chemotherapy
JP7213549B2 (ja) 2016-08-22 2023-01-27 シーエイチオー ファーマ インコーポレイテッド 抗体、結合性断片、および使用の方法
MA46660A (fr) 2016-10-18 2019-08-28 Seattle Genetics Inc Administration ciblée d'inhibiteurs de la voie de récupération de nicotinamide adénine dinucléotide
US20180118811A1 (en) 2016-10-19 2018-05-03 Invenra Inc. Antibody constructs
US11278629B2 (en) 2016-11-02 2022-03-22 Debiopharm International, S.A. Methods for improving anti-CD37 immunoconjugate therapy
KR20220147720A (ko) 2016-11-14 2022-11-03 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
CA3044391A1 (en) 2016-11-23 2018-05-31 Immunogen, Inc. Selective sulfonation of benzodiazepine derivatives
IL266917B2 (en) 2016-11-29 2023-10-01 Regeneron Pharma Conjugates of a drug and an antibody to the human prolactin receptor (PRLR) and their use in the combined treatment of PRLR-positive breast cancer
JP7244987B2 (ja) 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート
CA3045857A1 (en) 2016-12-22 2018-06-28 Universita Degli Studi Magna Graecia Catanzaro A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of cd43
HUE058664T2 (hu) 2016-12-23 2022-09-28 Immunogen Inc ADAM9-et célzó immunkonjugátumok és eljárások azok felhasználására
TW201825515A (zh) 2017-01-04 2018-07-16 美商伊繆諾金公司 Ｍｅｔ抗體以及其免疫結合物及用途
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
CN116785450A (zh) 2017-02-28 2023-09-22 伊缪诺金公司 具有自分解肽接头的类美登素衍生物和其缀合物
JP2020512312A (ja) 2017-03-24 2020-04-23 シアトル ジェネティックス， インコーポレイテッド グルクロニド薬物−リンカーの調製のためのプロセスおよびその中間体
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
TW201839001A (zh) 2017-04-20 2018-11-01 美商伊繆諾金公司 細胞毒性苯并二氮平衍生物及其綴合物
US20180311375A1 (en) * 2017-04-27 2018-11-01 Cadila Healthcare Limited Process of preparing antibody-drug conjugate
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
CN110799217A (zh) 2017-04-27 2020-02-14 西雅图基因公司 季铵化烟酰胺腺嘌呤二核苷酸补救途径抑制剂缀合物
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
JP7245793B2 (ja) 2017-06-30 2023-03-24 ザイムワークス ビーシー インコーポレイテッド 安定化したキメラＦａｂ
CN111565750B (zh) 2017-08-28 2023-11-03 安吉克公司 抗tm4sf1抗体及其使用方法
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2019133652A1 (en) 2017-12-28 2019-07-04 Immunogen, Inc. Benzodiazepine derivatives
TW202344272A (zh) 2018-04-13 2023-11-16 美商建南德克公司 穩定抗cd79b免疫結合物調配物
CN113227127A (zh) 2018-06-05 2021-08-06 伦敦大学国王学院 向胃肠系统递送酬载的btnl3/8导引构建体
JP2021528471A (ja) 2018-06-26 2021-10-21 イミュノジェン・インコーポレーテッド Ａｄａｍ９を標的とする免疫コンジュゲート、及び、その使用の方法
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
CN112566942A (zh) 2018-07-25 2021-03-26 第一三共株式会社 用于制造抗体-药物缀合物的有效方法
BR112021004656A2 (pt) 2018-09-26 2021-06-01 Jiangsu Hengrui Medicine Co., Ltd. conjugado fármaco-ligante de análogo exatecano, método para preparar o mesmo e aplicação do mesmo
TW202029980A (zh) 2018-10-26 2020-08-16 美商免疫遺傳股份有限公司 Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
CA3133155A1 (en) 2019-03-19 2020-09-24 Fundacio Privada Institut D'investigacio Oncologica De Vall Hebron Combination therapy for the treatment for cancer
WO2020191342A1 (en) 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 antibodies and drug conjugates
JP2022529583A (ja) 2019-03-29 2022-06-23 イミュノジェン・インコーポレーテッド 異常細胞増殖を阻害するまたは増殖性疾患を治療するための細胞毒性ビス－ベンゾジアゼピン誘導体及び細胞結合剤とのその複合体
CA3137373A1 (en) 2019-04-24 2020-10-29 Heidelberg Pharma Research Gmbh Amatoxin antibody-drug conjugates and uses thereof
FI3958977T3 (fi) 2019-04-26 2023-12-12 Immunogen Inc Kamptotesiinijohdannaisia
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
CN114341162A (zh) 2019-07-10 2022-04-12 赛博克萨2公司 作为治疗剂的细胞毒素的肽缀合物
BR112022000297A2 (pt) 2019-07-10 2022-03-15 Cybrexa 3 Inc Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos
US20220411436A1 (en) 2019-09-18 2022-12-29 Sichuan Baili Pharmaceutical Co., Ltd Camptothecin derivative and conjugate thereof
EP4036149A4 (en) 2019-09-26 2023-10-25 NOF Corporation HETEROBIFUNCTIONAL MONODISPERSPERED POLYETHYLENE GLYCOL WITH PEPTIDE LINKER
CN116925237A (zh) 2019-12-31 2023-10-24 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
CN113728013B (zh) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
MX2022009044A (es) 2020-01-22 2022-08-11 Shanghai Senhui Medicine Co Ltd Conjugado de farmaco de derivado de eribulin, metodo de preparacion y aplicacion del mismo en medicina.
US20210283125A1 (en) 2020-02-25 2021-09-16 Mediboston, Inc. Camptothecin derivatives and conjugates thereof
CN111195353B (zh) * 2020-03-19 2023-06-23 烟台迈百瑞国际生物医药股份有限公司 一种美登素类抗体药物偶联物及其应用
KR20220157425A (ko) 2020-03-25 2022-11-29 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 항체 약물 접합체의 제조 방법
AU2021243073A1 (en) 2020-03-25 2022-10-13 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising antibody drug conjugate and use thereof
CA3176248A1 (en) 2020-04-10 2021-10-14 Seagen Inc. Charge variant linkers
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
EP4178624A2 (en) 2020-07-07 2023-05-17 Bionecure Therapeutics, Inc. Maytansinoids as adc payloads and their use for the treatment of cancer
US20220378929A1 (en) 2021-02-25 2022-12-01 MediBoston Limted Anti-her2 antibody-drug conjugates and uses thereof
CN117279664A (zh) 2021-04-10 2023-12-22 普方生物制药美国公司 Folr1结合剂、其偶联物及其使用方法
CN117203238A (zh) 2021-04-23 2023-12-08 普方生物制药美国公司 Cd70结合剂、其偶联物及其使用方法
WO2023092099A1 (en) 2021-11-19 2023-05-25 Ardeagen Corporation Gpc3 binding agents, conjugates thereof and methods of using the same
WO2023169896A1 (en) 2022-03-09 2023-09-14 Astrazeneca Ab BINDING MOLECULES AGAINST FRα
WO2023170216A1 (en) 2022-03-11 2023-09-14 Astrazeneca Ab A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY
US20240108744A1 (en) 2022-07-27 2024-04-04 Mediboston Limited Auristatin derivatives and conjugates thereof
WO2024089013A1 (en) 2022-10-25 2024-05-02 Peptomyc, S.L. Combination therapy for the treatment of cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03161490A (ja) * 1989-10-25 1991-07-11 Immunogen Inc メイタンシノイドを含む細胞障害剤及び該細胞障害剤を有効成分とする医薬
WO2003057163A2 (en) * 2002-01-03 2003-07-17 Smithkline Beecham Corporation Methods for preparing immunoconjugates
WO2003068956A1 (en) * 2002-02-13 2003-08-21 Xoma Technology Ltd. Eukaryotic signal sequences for polypeptide expression and polypeptide display libraries
WO2003074081A1 (en) * 2002-02-28 2003-09-12 Mindset Biopharmaceuticals Usa Inc. SPECIFIC ANTIBODIES TO AMYLOID β PEPTIDE, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF

Family Cites Families (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
GB1603640A (en) 1977-07-20 1981-11-25 Gist Brocades Nv Enzyme particles
US4137230A (en) * 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4307016A (en) * 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4265814A (en) * 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
JPS5562090A (en) * 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) * 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55164687A (en) * 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) * 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55102583A (en) * 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) * 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) * 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) * 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) * 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) * 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) * 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (en) * 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
WO1982001188A1 (en) * 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) * 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) * 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) * 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
JPS57192389A (en) * 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
JPS58167592A (ja) 1982-03-26 1983-10-03 Takeda Chem Ind Ltd 新規メイタンシノイド化合物
LU86212A1 (fr) 1985-12-16 1987-07-24 Omnichem Sa Nouveaux conjugues de la vinblastine et de ses derives,procede pour leur preparation et compositions pharmaceutiques les contenant
US7838216B1 (en) 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US5395924A (en) 1986-03-20 1995-03-07 Dana-Farber Cancer Institute, Inc. Blocked lectins; methods and affinity support for making the same using affinity ligands; and method of killing selected cell populations having reduced non-selective cytotoxicity
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US4981979A (en) 1987-09-10 1991-01-01 Neorx Corporation Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
JPS6484959A (en) 1987-09-25 1989-03-30 Nec Corp System for connecting test line
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
US5217713A (en) 1988-12-27 1993-06-08 Takeda Chemical Industries, Ltd. Cytotoxic bispecific monoclonal antibody, its production and use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5705157A (en) 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
US5154924A (en) 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
FR2656555B1 (fr) * 1989-12-29 1994-10-28 Serimer Systeme mecanique de guidage automatique d'une ou plusieurs torches d'une unite de soudage a l'arc.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
SE9102074D0 (sv) 1991-07-03 1991-07-03 Kabi Pharmacia Ab Tomour antigen specific antibody
WO1993003741A1 (en) 1991-08-22 1993-03-04 Becton, Dickinson & Company Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US6022541A (en) 1991-10-18 2000-02-08 Beth Israel Deaconess Medical Center Immunological preparation for concurrent specific binding to spatially exposed regions of vascular permeability factor bound in-vivo to a tumor associated blood vessel
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
DE69334255D1 (de) 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker für Krebs und biosynthetisches Bindeprotein dafür
CA2076465C (en) 1992-03-25 2002-11-26 Ravi V. J. Chari Cell binding agent conjugates of analogues and derivatives of cc-1065
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
US7754211B2 (en) * 1992-04-10 2010-07-13 Research Development Foundation Immunotoxins directed against c-erbB-2(HER-2/neu) related surface antigens
JP2861631B2 (ja) 1992-05-06 1999-02-24 日本電気株式会社 Ｆｓｋ受信機
US6217869B1 (en) 1992-06-09 2001-04-17 Neorx Corporation Pretargeting methods and compounds
AU687346B2 (en) 1992-06-30 1998-02-26 Oncologix, Inc. A combination of anti-erbB-2 monoclonal antibodies and method of using
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
AU6527894A (en) 1993-03-30 1994-10-24 Trustees Of The University Of Pennsylvania, The Prevention of tumors with monoclonal antibodies against (neu)
EP1231274A3 (en) 1994-11-21 2002-10-09 The University Of Leeds Modified porteinase inhibitors
US5679648A (en) 1994-11-30 1997-10-21 The University Hospital Methods for the treatment and prevention of fungal infections by administration of 3'-deoxypurine nucleosides
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
AU6113396A (en) 1995-06-14 1997-01-15 Regents Of The University Of California, The Novel high affinity human antibodies to tumor antigens
US5614692A (en) 1995-06-30 1997-03-25 Tracor Aerospace, Inc. Shaped-charge device with progressive inward collapsing jet
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US5919815A (en) 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US5968517A (en) 1996-05-23 1999-10-19 Duncan; Kelvin Winston Process for extraction of proanthocyanidins from botanical material
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
CA2263420A1 (en) 1996-08-30 1998-03-05 James Edward Ray Pharmaceutical compounds
JPH1084959A (ja) * 1996-09-06 1998-04-07 Nobuyoshi Shimizu 細胞表面レセプターに対するモノクローナル抗体ならびにそのフラグメントの結合体ならびに複合体、それらの製法ならびに細胞への嵌入方法および使用方法
HU224196B1 (hu) * 1996-09-20 2005-06-28 Meiji Seika Kaisha Ltd. Cefditoren-pivoxil kristályos formája, és eljárás annak előállítására
BR9712410A (pt) 1996-10-18 1999-10-19 Genentech Inc Anticorpo isolado, composição, ácido nucleico, vetor, célula hospedeira, método para fazer um anticorpo anti-erbb2, método para a determinação da presença de erbb2, kit, método paa a indução da morte celular e artigo manufaturado
ES2215241T3 (es) 1996-11-06 2004-10-01 Sequenom, Inc. Procedimiento de espectrometria de masa.
CA2274641A1 (en) 1996-12-12 1998-06-18 David Richard Corbin Improved packaging composition
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
CA2297070A1 (en) 1997-08-01 1999-02-11 Morphosys Ag Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex
US20030060612A1 (en) 1997-10-28 2003-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
DE69839942D1 (de) 1997-10-29 2008-10-09 Genentech Inc Verwendung des wnt-1 induzierten sekretierten polypeptids wisp-1
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6914130B2 (en) 1998-06-17 2005-07-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US6747055B1 (en) * 1998-07-17 2004-06-08 The United States Of America As Represented By The Department Of Health And Human Services Water-soluble drugs and methods for their production
WO2000020579A1 (en) 1998-10-02 2000-04-13 Mcmaster University Spliced form of erbb-2/neu oncogene
IL144559A0 (en) 1999-03-01 2002-05-23 Genentech Inc Antibodies for cancer therapy and diagnosis
BRPI0009448B8 (pt) 1999-04-01 2021-05-25 Univ Texas kit para uso no tratamento de uma neoplasia em um mamífero
CA2372053C (en) 1999-04-28 2008-09-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
PL200134B1 (pl) 1999-05-07 2008-12-31 Genentech Inc Zastosowanie przeciwciała anty-CD20
AU4809299A (en) 1999-05-12 2000-12-05 Array Ab Direct printing device with cleaning unit
CA2374085C (en) 1999-05-14 2015-12-29 Genentech, Inc. Tumour treatment with anti-erbb2 antibodies
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
BR122014028365B8 (pt) 1999-06-25 2021-07-06 Genentech Inc artigo industrializado compreendendo um primeiro recipiente que compreende uma composição de humab4d5-8 nele contida e um segundo recipiente que compreende uma composição rhumab 2c4 nele contida
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
HU230586B1 (hu) 1999-06-25 2017-02-28 Genentech, Inc. Anti-ErbB antitest/maytansinoid konjugátumok alkalmazása rákos betegségek kezelésére szolgáló gyógyszer előállítására
CA2383493C (en) 1999-06-25 2010-08-10 Genentech, Inc. Treating prostate cancer with anti-erbb2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US6362342B1 (en) 1999-06-29 2002-03-26 Lion Bioscience Ag Triazole compounds and methods of making same
WO2001003734A1 (en) 1999-07-12 2001-01-18 Genentech, Inc. Blocking immune response to a foreign antigen using an antagonist which binds to cd20
US6531131B1 (en) * 1999-08-10 2003-03-11 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for Neisseria meningitidis
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
DE60042693D1 (de) 1999-08-27 2009-09-17 Genentech Inc Dosierung für die behandlung mit anti erbb2-antikörpern
US7030231B1 (en) 1999-09-30 2006-04-18 Catalyst Biosciences, Inc. Membrane type serine protease 1 (MT-SP1) and uses thereof
US7303749B1 (en) 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
EP2266607A3 (en) 1999-10-01 2011-04-20 Immunogen, Inc. Immunoconjugates for treating cancer
BE1012928A6 (nl) 1999-10-07 2001-06-05 Hoeberigs Jean Marie Mathieu Cilinderoven voor verwarming van frites met hete lucht.
EP1226177B1 (en) 1999-10-29 2008-07-09 Genentech, Inc. Anti-prostate stem cell antigen (psca) antibody compositions and methods of use
US6824780B1 (en) 1999-10-29 2004-11-30 Genentech, Inc. Anti-tumor antibody compositions and methods of use
ATE349438T1 (de) 1999-11-24 2007-01-15 Immunogen Inc Cytotoxische wirkstoffe enthaltend taxane und deren therapeutische anwendung
NZ520482A (en) * 2000-02-11 2004-12-24 Lilly Co Eli Selective N-acylation of A82846 glycopeptide analogs that are ueful for treating staphylococcal infection
EP1257296A2 (en) 2000-02-24 2002-11-20 Genentech, Inc. Caspase activated prodrugs therapy
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
NZ521540A (en) 2000-04-11 2004-09-24 Genentech Inc Multivalent antibodies and uses therefor
AU2001283740A1 (en) 2000-08-17 2002-02-25 University Of British Columbia Chemotherapeutic agents conjugated to p97 and their methods of use in treating neurological tumours
US6596503B1 (en) 2000-08-18 2003-07-22 East Carolina University Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof
US6333410B1 (en) * 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
CA2420140A1 (en) 2000-08-24 2002-02-28 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
JP4450555B2 (ja) 2000-12-28 2010-04-14 協和発酵キリン株式会社 新規モノクローナル抗体
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
CA2633171C (en) 2001-06-20 2012-11-20 Genentech, Inc. Antibodies against tumor-associated antigenic target (tat) polypeptides
BR0212641A (pt) * 2001-09-05 2005-04-12 Genentech Inc Método para identificação de antìgeno, método para a produção de um composto, método para a inibição de proliferação de células, método para o tratamento de câncer, composição e seu uso
US20040235068A1 (en) 2001-09-05 2004-11-25 Levinson Arthur D. Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
US20080085283A1 (en) 2001-09-05 2008-04-10 Levinson Arthur D Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
US20030109682A1 (en) * 2001-09-07 2003-06-12 Daniel Santi Maytansines and maytansine conjugates
NZ573831A (en) 2001-09-18 2010-07-30 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor, particularly breast tumor - TAT193
US20050238650A1 (en) 2002-04-17 2005-10-27 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US6716821B2 (en) * 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
JP2006502110A (ja) 2002-07-03 2006-01-19 イミュノジェン・インコーポレーテッド 非放出Ｍｕｃ１およびＭｕｃ１６に対する抗体、およびその使用
ATE499116T1 (de) * 2002-08-16 2011-03-15 Immunogen Inc Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln
KR20050048615A (ko) 2002-08-19 2005-05-24 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
CN102940889A (zh) * 2003-05-14 2013-02-27 伊缪诺金公司 药物缀合物组合物
US7276497B2 (en) * 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
WO2005009369A2 (en) 2003-07-21 2005-02-03 Immunogen, Inc. A ca6 antigen-specific cytotoxic conjugate and methods of using the same
US7754441B2 (en) 2003-11-17 2010-07-13 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
JP3991983B2 (ja) 2003-12-19 2007-10-17 日産自動車株式会社 車両の駆動制御装置
CA2551813C (en) 2003-12-24 2014-08-12 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
EP1718667B1 (en) 2004-02-23 2013-01-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
NZ580115A (en) 2004-09-23 2010-10-29 Genentech Inc Cysteine engineered antibody light chains and conjugates
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
US7989595B2 (en) 2005-06-20 2011-08-02 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7195520B1 (en) 2006-07-18 2007-03-27 Chung-Chuan Huang Connector for antenna
EP3692988A3 (en) 2008-03-18 2020-10-14 Genentech, Inc. Combinations of an anti-her2 antibody-drug conjugate and 5-fu, anti-vegf antibody, carboplatin or abt-869 and methods of use
KR20230003298A (ko) * 2008-04-30 2023-01-05 이뮤노젠 아이엔씨 가교제 및 그 용도
US20110165155A1 (en) 2009-12-04 2011-07-07 Genentech, Inc. Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
MX338932B (es) 2010-03-12 2016-05-06 Immunogen Inc Moleculas de union cd37 y sus inmunoconjugados.
BR112013014316A2 (pt) 2010-12-09 2016-09-27 Genentech Inc tratamento de câncer her2-positivo com paclitaxel e trastuzumabe-mcc-dm1

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03161490A (ja) * 1989-10-25 1991-07-11 Immunogen Inc メイタンシノイドを含む細胞障害剤及び該細胞障害剤を有効成分とする医薬
WO2003057163A2 (en) * 2002-01-03 2003-07-17 Smithkline Beecham Corporation Methods for preparing immunoconjugates
WO2003068956A1 (en) * 2002-02-13 2003-08-21 Xoma Technology Ltd. Eukaryotic signal sequences for polypeptide expression and polypeptide display libraries
WO2003074081A1 (en) * 2002-02-28 2003-09-12 Mindset Biopharmaceuticals Usa Inc. SPECIFIC ANTIBODIES TO AMYLOID β PEPTIDE, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013504585A (ja) * 2009-09-09 2013-02-07 セントローズ， エルエルシー 細胞外標的化薬物複合体
JP2016056209A (ja) * 2009-09-09 2016-04-21 セントローズ， エルエルシー 細胞外標的化薬物複合体
JP2013506709A (ja) * 2009-10-06 2013-02-28 イミュノジェン・インコーポレーテッド 有効なコンジュゲートおよび親水性リンカー
JP2016106222A (ja) * 2009-10-26 2016-06-16 ネステク ソシエテ アノニム 抗ｔｎｆ薬及び自己抗体の検出用アッセイ
JP2013544253A (ja) * 2010-11-17 2013-12-12 ジェネンテック， インコーポレイテッド アラニニルメイタンシノール抗体コンジュゲート
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
JP2016518332A (ja) * 2013-03-13 2016-06-23 ノバルティス アーゲー 抗体薬物コンジュゲート
WO2019150985A1 (ja) * 2018-01-31 2019-08-08 国立大学法人東京大学 抗体薬物複合体及びそれを含む医薬組成物

Also Published As

Publication number Publication date
AU2004282491C1 (en) 2011-06-30
PT1689846E (pt) 2013-05-08
NO2016001I1 (no) 2016-01-26
CY1113984T1 (el) 2016-07-27
ECSP066461A (es) 2007-05-30
KR20130102649A (ko) 2013-09-17
HRP20130412T1 (en) 2013-06-30
KR20060130552A (ko) 2006-12-19
JP2012006928A (ja) 2012-01-12
US8563509B2 (en) 2013-10-22
US20050169933A1 (en) 2005-08-04
EP1689846A4 (en) 2010-08-04
EP2596804A2 (en) 2013-05-29
CY2014002I1 (el) 2020-05-29
CA2542128A1 (en) 2005-04-28
KR101476082B1 (ko) 2014-12-23
JP2017200934A (ja) 2017-11-09
CN108578710B (zh) 2021-11-19
NZ545195A (en) 2010-07-30
KR101573124B1 (ko) 2015-12-01
EA200600752A1 (ru) 2007-08-31
AU2010212291C1 (en) 2012-11-29
EA010508B1 (ru) 2008-10-30
US20140154804A1 (en) 2014-06-05
EP1689846B1 (en) 2013-03-27
AU2010212291A1 (en) 2010-09-02
AU2010212291B2 (en) 2012-05-24
NO2016001I2 (no) 2016-01-26
NZ583844A (en) 2011-06-30
NO337458B1 (no) 2016-04-18
EP2596803A3 (en) 2013-09-11
HK1244452A1 (zh) 2018-08-10
EP2612682A3 (en) 2013-09-25
US8088387B2 (en) 2012-01-03
JP5718745B2 (ja) 2015-05-13
NO20061772L (no) 2006-04-21
US20170226220A1 (en) 2017-08-10
BRPI0415448A8 (pt) 2019-08-13
IL173625A0 (en) 2006-07-05
IL173625A (en) 2016-07-31
US8685920B2 (en) 2014-04-01
US20080171865A1 (en) 2008-07-17
US20080145374A1 (en) 2008-06-19
US10844135B2 (en) 2020-11-24
CN103223174A (zh) 2013-07-31
US20120226025A1 (en) 2012-09-06
CN107198778A (zh) 2017-09-26
JP2024059792A (ja) 2024-05-01
IL235253B (en) 2018-04-30
AU2004282491A1 (en) 2005-04-28
CN108578710A (zh) 2018-09-28
US7989598B2 (en) 2011-08-02
JP5926759B2 (ja) 2016-05-25
AU2004282491B2 (en) 2010-12-23
CA3139478A1 (en) 2005-04-28
IL246605A (en) 2017-08-31
LU92336I2 (fr) 2014-02-17
JP2014177463A (ja) 2014-09-25
WO2005037992A2 (en) 2005-04-28
US8198417B2 (en) 2012-06-12
JP2020189854A (ja) 2020-11-26
EP2612682A2 (en) 2013-07-10
SI1689846T1 (en) 2013-06-28
US8163888B2 (en) 2012-04-24
JP2019011363A (ja) 2019-01-24
US20110281856A1 (en) 2011-11-17
US20210261683A1 (en) 2021-08-26
EP1689846A2 (en) 2006-08-16
US20080171856A1 (en) 2008-07-17
JP2016135786A (ja) 2016-07-28
ES2404304T3 (es) 2013-05-27
KR20120034800A (ko) 2012-04-12
KR101343676B1 (ko) 2013-12-20
LU92336I9 (US20080114153A1-20080515-C00016.png) 2019-01-16
WO2005037992A3 (en) 2009-04-23
PL1689846T3 (pl) 2013-07-31
JP2019142864A (ja) 2019-08-29
DK1689846T3 (da) 2013-05-06
IL214788A0 (en) 2011-11-30
US20080114153A1 (en) 2008-05-15
CA2542128C (en) 2022-01-11
JP2022068295A (ja) 2022-05-09
EP2596803A2 (en) 2013-05-29
EP2596804A3 (en) 2013-09-18
HUS1300075I1 (hu) 2014-02-28
KR20140033003A (ko) 2014-03-17
CY2014002I2 (el) 2020-05-29
BE2013C075I2 (US20080114153A1-20080515-C00016.png) 2023-12-18
BRPI0415448A (pt) 2006-12-05

Similar Documents

Publication Publication Date Title
US20210261683A1 (en) Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070705

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110330

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110406

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110428

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110511

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110603

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110705

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110914

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111214

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120203

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120210

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120806